Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20033227 | 0.78 | CA1 (0.31) | CA1CA2 | |
| SCHEMBL13653078 | 0.74 | — | — | |
| SCHEMBL21761160 | 0.72 | CA1 (0.37) | CA1CA2ALDH1A1 | |
| SCHEMBL11033710 | 0.72 | CA1 (0.37) | CA1CA2ALDH1A1 | |
| SCHEMBL20988317 | 0.70 | LMNA (0.40) | CA1LMNASMN1; SMN2 | |
| SCHEMBL14593912 | 0.69 | — | — | |
| SCHEMBL25867700 | 0.69 | ALDH1A1 (0.32) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL10486710 | 0.67 | MAPT (0.34) | ALDH1A1HPGDMEN1KMT2ALMNA | |
| SCHEMBL246883 | 0.67 | — | — | |
| SCHEMBL21761204 | 0.67 | CA1 (0.32) | CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968199-B2 | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSIT (US) | 2020-05-19 | — | — | US | disclosed |
| US-10596184-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2020-03-24 | — | — | US | disclosed |
| US-20200062727-A1 | CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10323061-B2 | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSITY OF ARIZONA | 2019-05-09 | — | — | US | disclosed |
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-9938301-B2 | Dihydropyrimido fused ring derivative as HBV inhibitor | QILU PHARMACEUTICAL CO., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | CA1 4688/4885CA2 4099/4885ALDH1A1 2736/4885 |
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | IDO1, IDO2, MMP1 | CA1 4143/4885CA2 3337/4885ALDH1A1 161/4885 |
| US-10596184-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | PIK3R5, PIK3R1, PIK3R3 | CA1 4336/4885CA2 3793/4885ALDH1A1 3781/4885 |
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | CA1 1754/4885CA2 1563/4885ALDH1A1 2128/4885 |
| US-20200062727-A1 | CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, BCL2, AIFM1 | CA1 3839/4885CA2 4202/4885ALDH1A1 1821/4885 |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | IDO1, INMT, MMP1 | CA1 4298/4885CA2 3607/4885ALDH1A1 295/4885 |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | CNR1, CNR2, OPRL1 | CA1 3166/4885CA2 2017/4885ALDH1A1 1706/4885 |
| US-10968199-B2 | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, BCL2, AIFM1 | CA1 3839/4885CA2 4202/4885ALDH1A1 1821/4885 |
| US-10323061-B2 | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | CA1 3328/4885CA2 3210/4885ALDH1A1 2323/4885 |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MRPL21, MRPS34, MRPL37 | CA1 4853/4885CA2 3908/4885ALDH1A1 4667/4885 |
| US-10022387-B2 | Aza-heteroaryl compounds as PI3K-gamma inhibitors | PIK3R5, PIK3R1, PIK3R3 | CA1 4336/4885CA2 3793/4885ALDH1A1 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.